| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 31.69 | 61.9% | 556.1% |
| Total Income | 31.69 | 61.9% | 556.1% |
| Expenditure | 82.72 | 4.3% | 20.9% |
| PBT | -62.84 | 1263.7% | 6.5% |
| Net Profit | -62.84 | 1263.7% | 6.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.18 | 1000.0% | 5.9% |
Nuvation Bio Reports Q2 2026 Financial Results and Provides Business Update
06 Aug 2026 · 6 Aug, 5:02 pm
Summary
Nuvation Bio reported total revenue of $31.7 million for the second quarter of 2026, including $23.2 million in net product revenue for IBTROZI®. The company highlighted IBTROZI's strong market position as the most prescribed ROS1 TKI and noted a significant increase in TKI-naïve patient starts. Positive long-term data for safusidenib was also announced, leading to an expansion of its clinical program for IDH1-mutant glioma. The company ended the quarter with a strong cash position of $661.0 million.
Key Highlights
- 1
Nuvation Bio reported $31.7 million in total revenue for the second quarter of 2026, with $23.2 million specifically from net product revenue for IBTROZI®.
- 2
IBTROZI® is the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026, based on IQVIA claims data from the first five months of the year.
- 3
Approximately 85% of new IBTROZI® patient starts in Q2 2026 were TKI-naïve, representing a quarter-over-quarter growth of approximately 30% in this setting.
- 4
The company announced positive updated long-term Phase 2 data for safusidenib, supporting a significant expansion of its clinical program for IDH1-mutant glioma.
- 5
Nuvation Bio maintained a robust balance sheet with $661.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026, further strengthened by an additional $36.5 million in net proceeds secured in July 2026.
- 6
For the three months ended June 30, 2026, collaboration and license agreements revenue was $8.5 million, an increase from $3.6 million in the prior year period.
Management Comments
David Hung
IBTROZI is now the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026, based on IQVIA claims data from the first five months of the year, reflecting the medical community’s growing conviction that IBTROZI’s durability profile belongs at the front of the treatment sequence. Consistent with this, approximately 85% of new prescriptions this quarter were for TKI-naïve patients who have the potential to be on therapy for many years. The continued shift toward TKI-naïve use highlights the increasing recognition of our long-term follow-up data in TRUST-I, which show a confirmed 90% response rate and a median duration of response of 50 months. This efficacy profile, combined with a generally tolerable safety profile and as the only brain-penetrant ROS1 inhibitor today without a CNS warning and precaution in its label, reinforces our belief that IBTROZI is becoming the standard of care for patients with advanced ROS1-positive NSCLC. We are equally excited about the progress of safusidenib, with our updated Phase 2 data showing further deepening and durable responses in IDH1-mutant gliomas. We now plan to evaluate the potential of this investigational medicine across the broad spectrum of patients in hopes of fulfilling our ultimate goal of providing an effective therapy for nearly every patient with this disease. During the second quarter, we also strengthened our balance sheet through our convertible notes offering, providing us with the financial flexibility to continue to invest in growing our portfolio.
Informational and educational content only. Not investment advice.